Orelabrutinib Versus Chemoimmunotherapy in Treatment-NaïVe Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Randomized, Phase III Trial

Scientists demonstrated that orelabrutinib significantly improves progression-free survival and response rates over chemoimmunotherapy as a first-line treatment for chronic lymphocytic leukemia/small lymphocytic lymphoma.